Delving into the Latest Updates on Clopidogrel Bisulfate with Synapse

Overview

Basic Info

SummaryClopidogrel Bisulfate, a medication trademarked as Plavix®, was approved by Bristol Myers Squibb in the US in 1997. Its mechanism of action is to inhibit P2Y12 receptors, which reduces platelet activation and aggregation. This subsequently decreases the risk of blood clots and their potentially fatal consequences. Clopidogrel is indicated for treating myocardial infarction, stroke, peripheral vascular disease, coronary artery disease, and cerebrovascular disease. With its role as an antiplatelet agent, Clopidogrel proves invaluable in preventing severe complications from blood clots such as heart attacks, strokes, and even death. The drug has shown efficacy in the management and prevention of cardiovascular events, making it an essential medication in modern medicine.

Drug Type

Small molecule drug

Synonyms

clopidogrel, Clopidogrel Bisufate, Clopidogrel bisulfate (USP)

+ [31]

Target

P2Y12 receptor

Mechanism

P2Y12 receptor antagonists(Purinergic receptor P2Y12 antagonists)

Therapeutic Areas

Nervous System DiseasesCardiovascular Diseases

Active Indication

Non-Q wave myocardial infarctionAtherosclerosisNon ST segment elevation acute coronary syndrome+ [14]

Inactive Indication

Coronary Artery DiseaseHeart ArrestHeart Defects, Congenital+ [4]

Originator Organization

Bristol Myers Squibb Co.

Active Organization

Zentiva ksHCS bvbaPharmathen SA

+ [10]

Inactive Organization

Archie Samuel Sro

Bristol Myers Squibb Co.

Sanofi SA

+ [5]

Drug Highest PhaseApproved

First Approval Date

US (17 Nov 1997),

Myocardial InfarctionStroke

RegulationPriority Review (CN)

Login to view First Approval Timeline

Structure

Molecular FormulaC16H18ClNO6S2

InChIKeyFDEODCTUSIWGLK-RSAXXLAASA-N

CAS Registry120202-66-6

To manage the ST-segment elevation myocardial infarction (STEMI) caused by plaque rupture, triggers platelet activation/aggregation and thrombin generation, requires dual (platelet and coagulation) pathway inhibition. However, triple antithrombotic therapy with standard dual antiplatelet therapy (DAPT) and oral anticoagulant (OAC) in the STEMI setting is a challenge, since that increase in potential risk of bleeding.
Although the incidence of left ventricular thrombus (LVT) formation after STEMI decreased in modern reperfusion therapy, including primary percutaneous coronary intervention (PCI), remains at 4% to 26%, especially that complicated by anterior STEMI. The recommendation of an OAC prophylactic therapy for preventing LVT formation in current STEMI guidelines is limited. How to optimize antithrombotic therapy to balance the bleeding-thrombotic profile, and prevent LVT formation is challenging, since insufficient evidence is available from randomized trials.
Century Clot analyzer is point-of-care testing that could assess the coagulate state: normal, hypo-coagulable, or hyper-coagulable states according to clot rate (CR) value. Whether Century Clot-guided rivaroxaban prophylactic therapy (2.5 mg twice daily, if the hypercoagulable state, defined as CR ≥24) in combination with standard DAPT could reduce LVT formation without increasing major bleeding is uncertain.

Start Date01 Apr 2024

Sponsor / Collaborator

Zunyi Medical University

CTR20240407 / CompletedNot Applicable

硫酸氢氯吡格雷片人体生物等效性试验

[Translation] Bioequivalence study of clopidogrel bisulfate tablets in humans

主要研究目的本研究考察空腹及餐后条件下单次口服受试制剂硫酸氢氯吡格雷片（规格：75 mg/片，生产单位：杭州民生药业股份有限公司）与参比制剂硫酸氢氯吡格雷片（商品名：波立维®，规格：75 mg/片，生产单位：Sanofi Wint hrop Industrie）在健康成年受试者体内的药代动力学，评价空腹和餐后口服两种制剂的生物等效性。次要研究目的观察单次口服 75 mg 的受试制剂硫酸氢氯吡格雷片或参比制剂硫酸氢氯吡格雷片（商品名：波立维®，75 mg）在健康受试者中的安全性。

[Translation]

Main study objectives This study investigated the pharmacokinetics of the test preparation clopidogrel bisulfate tablets (specification: 75 mg/tablet, manufacturer: Hangzhou Minsheng Pharmaceutical Co., Ltd.) and the reference preparation clopidogrel bisulfate tablets (trade name: Plavix®, specification: 75 mg/tablet, manufacturer: Sanofi Wint hrop Industrie) in healthy adult subjects after a single oral administration under fasting and postprandial conditions, and evaluated the bioequivalence of the two preparations after fasting and postprandial oral administration. Secondary study objectives Observe the safety of a single oral administration of 75 mg of the test preparation clopidogrel bisulfate tablets or the reference preparation clopidogrel bisulfate tablets (trade name: Plavix®, 75 mg) in healthy subjects.

Start Date06 Mar 2024

Sponsor / Collaborator

Hai Nan Yao Gu Yun Sheng Wu Ke Ji You Xian Gong Si

NCT05643651 / Not yet recruitingPhase 4IIT

Rivaroxaban Versus Warfarin for Thromboprophylaxis in Children With Giant Coronary Artery Aneurysms After Kawasaki Disease: a Multicenter, Open-label, Parallel, Exploratory, Randomized Controlled Trial

Based on population pharmacokinetic model-based simulation, a 15 mg-equivalent, age-, and bodyweight-adjusted dosing regimen for Chinese children with giant coronary artery aneurysms after acute Kawasaki disease was proposed. This exploratory trial aims to evaluate the feasibility, safety and effectiveness of rivaroxaban compared to warfarin for thromboprophylaxis in children with giant coronary artery aneurysms after Kawasaki disease

Start Date01 Mar 2024

Sponsor / Collaborator

Paediatrics Hospital Affiliated To Fudan University

100 Clinical Results associated with Clopidogrel Bisulfate

Login to view more data

100 Translational Medicine associated with Clopidogrel Bisulfate

Login to view more data

100 Patents (Medical) associated with Clopidogrel Bisulfate

Login to view more data

2,045

Literatures (Medical) associated with Clopidogrel Bisulfate

01 Mar 2024·Phytomedicine : international journal of phytotherapy and phytopharmacology

Clinical efficacy and safety of Panax notoginseng saponins in treating chronic obstructive pulmonary disease with blood hypercoagulability: A meta-analysis of randomized controlled trials

Review

Author: Zhang, Xinyu ; Zhang, Qiong ; Zhang, He ; Shi, Xia ; Zhang, Jie ; Zhang, Haiyan ; Zhou, Ruiling ; Zhang, Wen ; Wang, Bing

BACKGROUND:

Panax notoginseng saponins (PNS) are the primary active components of an ancient Chinese herb Panax notoginseng. Hypercoagulable state of blood (HCS) is an independent risk factor and a cause of death in chronic obstructive pulmonary disease (COPD). Several vivo studies have demonstrated the use of PNS preparations for treating COPD with HCS.

PURPOSE:

This study aimed to systematically evaluate the clinical efficacy and safety of PNS preparations in treating COPD with HCS.

STUDY DESIGN:

Meta-analysis of the randomized controlled trials (RCTs) was conducted to review data.

METHODS:

RCTs on the treatment of COPD with HCS and PNS preparations were searched from PubMed, Cochrane Library, Embase, Web of Science, Chinese National Knowledge Infrastructure, Vip Information Database, Wanfang data, and Chinese Biomedical Literature Database. Relevant data were extracted from the included studies and methodological quality evaluation was performed. R language (version 4.2.3) was applied for the meta-analysis.

RESULTS:

Twenty RCTs involving 1831 patients were analyzed. The results revealed that PNS preparations considerably increased the total clinical efficiency, improved forced expiratory volume in one second percent of predicted, and forced expiratory volume/forced vital capacity ratio. Further, PNS preparations improved fibrinogen, plasma d-dimer, whole blood viscosity at high cut, whole blood viscosity at low cut, and plasma viscosity levels. The results obtained for activated partial thromboplastin and prothrombin times were not statistically significant. Finally, PNS preparations increased partial pressure of oxygen and decreased carbon dioxide pressure.

CONCLUSION:

This is the first relatively comprehensive systematic review of the clinical efficacy and safety of PNS preparations for treating COPD with HCS. The study revealed that PNS preparations considerably improve lung function, hypoxia, and blood hypercoagulability in patients with COPD and HCS without increasing the risk of hemorrhage and has a good safety profile; therefore, it can be used as a new modulating agent and anticoagulant.

01 Mar 2024·Cartilage

Osteochondral Lesions of the Subtalar Joint: Clinical Outcomes in 11 Patients

Article

Author: Dahmen, Jari ; Weiss, Matthew B ; Azam, Mohammad T ; Kennedy, John G ; Stufkens, Sjoerd A S ; Rikken, Quinten G H ; Ter Laak Bolk, Carlijn ; Butler, James J ; Kerkhoffs, Gino M M J ; Buck, Tristan M F

Objective:

The purpose of this retrospective case series was to evaluate clinical outcomes following both conservative treatment and arthroscopic bone marrow stimulation (BMS) for the management of symptomatic subtalar osteochondral lesions (OCLs).

Design:

All symptomatic subtalar OCLs with a minimum of 12 months follow-up having undergone either a conservative management or arthroscopic procedure were included. Patient-reported outcomes were collected via questionnaires consisting of the Foot and Ankle Outcome Score (FAOS), Numeric Rating Scale (NRS) of pain in rest, during walking, during stair climbing, and during running. In addition, return to sports data, return to work data, reoperations, and complications were collected and assessed. In total, 11 patients across 2 academic institutions were included (3 males, 8 females). The median age was 43 years (interquartile range [IQR]: 32-53).

Results:

All patients underwent conservative treatment first; in addition, 9 patients underwent subtalar arthroscopic debridement with or without BMS. The median follow-up time was 15 months (IQR: 14-100). In the surgically treated group, the median NRS scores were 2 (IQR: 1-3) during rest, 3 (IQR: 2-4) during walking, 4 (IQR: 4-5) during stair climbing, 5 (IQR: 4-5) during running and the median FAOS score at final follow-up was 74 (IQR: 65-83). In the conservatively treated patients, the median NRS scores were all 0 (IQR: 0-0) and the median FAOS scores were 90 (IQR: 85-94). In the group of surgical treated patients, 4 were able to return to the same level of sports, 2 returned to a lower level of sports. Both conservatively treated patients returned to the sport and the same level of prior participation. All patients except one in the surgical group returned to work.

Conclusions:

This retrospective case series demonstrated that a high number of patients converted to surgery after initial conservative treatment. In addition, debridement and BMS show good clinical outcomes for the management of symptomatic subtalar OCLs at short-term follow-up. No complications nor secondary surgical procedures were noted in the surgically treated group. The high rate of failure of conservative treatment suggests that surgical intervention for symptomatic subtalar OCLs can be the primary treatment strategy; however, further research is warranted in light of the small number of patients.

01 Feb 2024·Critical reviews in oncology/hematology

Brain metastases and next-generation anticancer therapies: a survival guide for clinicians

Review

Author: Barigazzi, Chiara ; van den Bent, Martin ; Losurdo, Agnese ; Simonelli, Matteo ; Persico, Pasquale ; Pessina, Federico ; Navarria, Piera ; Di Muzio, Antonio ; Santoro, Armando ; Dipasquale, Angelo

Historically, patients with brain metastases (BMs) have been characterized by few systemic treatment options and poor prognosis. The recent introduction of next-generation anticancer therapies such as molecular targeted agents and immunotherapy have revolutionized the clinical decision-making process of this sub-population, posing new challenges to physicians. In this review, current evidence for the use of checkpoint inhibitors and targeted therapies in patients with BMs are discussed, with a focus on lung cancer, breast cancer, melanoma and renal cell carcinoma, providing suggestions and potential workflows for daily clinical practice. Several other on-going and future challenges, such as clinical trials design, ways to improve CNS penetration of novel drugs and unique molecular characteristics of BMs, are also discussed. The aim is producing an updated and easy-to-read guide for physicians, to improve decision-making in clinical practice.

73

News (Medical) associated with Clopidogrel Bisulfate

10 Jun 2024

·www.globenewswire.com

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform the Board to Lead C4T into Next Phase of Growth WATERTOWN, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced changes to its Board of Directors as part of the Company’s aspiration to become a fully integrated biotechnology company. Ron Cooper, a global biopharmaceutical executive experienced across discovery, development and commercialization, has been appointed chairman of C4T’s Board of Directors. Bruce Downey, who served as chairman between June 2022 and June 2024, remains a member of the Board of Directors. As part of C4T’s continued Board evolution with this appointment, Glenn Dubin, who has served on C4T’s Board of Directors since 2021, has decided to step down from the Board of Directors. “I am honored to become the next chairman of the Board of Directors of C4 Therapeutics where I expect to leverage my experience building fully integrated global biopharmaceutical companies to help C4T continue to deliver on the promise of targeted protein degradation,” said Ron Cooper. “Targeted protein degradation is a quickly evolving field with immense potential, and I am excited to work with the Board and management team to keep C4T at the forefront of this modality and help improve patients’ lives.” Ron Cooper most recently served as president and chief executive officer of Albireo Pharma, a fully integrated, global, commercial biopharmaceutical company that was acquired by Ipsen in March 2023. Earlier in his career, Mr. Cooper spent nearly 30 years at Bristol-Myers Squibb (BMS) in roles of increasing responsibility in sales, marketing and general management, most recently serving as President, Europe. At BMS, he played a leadership role in several successful product launches, including Abilify®, Atripla®, Eliquis®, Plavix®, Sprycel® and Yervoy®. Mr. Cooper currently serves on the Board of Directors of Generation Bio. “It has been my pleasure to serve as chairman and help C4T broaden the expertise of our Board by appointing several leaders with deep experience across clinical development, medical affairs, regulatory strategy, capital markets and commercialization. I look forward to working with Ron and our outstanding Board to help C4T capitalize on the opportunities ahead,” said Bruce Downey. “On behalf of the Board, I would like to thank Glenn Dubin for his support of C4T as he steps down so we can welcome Ron’s extensive pharmaceutical and biotechnology expertise to help lead the company in this next exciting phase. We appreciate Glenn’s contributions and wish him the best.” “As we pursue our vision to become a fully integrated biotechnology company, we are thrilled to have Ron’s experience helping companies successfully bring products through discovery, development and commercialization,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “We have an exciting path ahead and the entire C4T team remains focused on advancing our pipeline to deliver on the potential of targeted protein degradation science for patients searching for new therapies.” About C4 TherapeuticsC4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com. Forward-Looking StatementsThis press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; and our ability to fund our future operations. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized; and the risk that sufficient capital to fund our future operations will be available to us on acceptable terms or at the times required. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law. Contacts:Investors: Courtney SolbergSenior Manager, Investor RelationsCSolberg@c4therapeutics.com Media: Loraine Spreen Senior Director, Corporate Communications & Patient Advocacy LSpreen@c4therapeutics.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a06f09c7-3115-4f0d-93c9-bb23d667fe40

Executive ChangeAcquisition

31 May 2024

·firstwordpharma.com

CHMP nods for haemophilia B gene therapy, chikungunya vaccine lead decisions from May meeting

At its May meeting, the European Medicines Agency's drug advisory body recommended 14 new medicines for approval, including one biosimilar and five generics, while it also backed extended labelling for seven treatments. In addition, the Committee for Medicinal Products for Human Use (CHMP) confirmed a negative opinion following a re-examination, and there were two marketing application withdrawals. All of the decisions can be found detailed below.Positive recommendations on new medicines: Takeda’s enzyme replacement therapy Adzynma (rADAMTS13) for the treatment of children and adult patients with congenital thrombotic thrombocytopenic purpura. SIFI’s Akantior (polyhexanide) for the treatment of acanthamoeba keratitis. CStone Pharmaceuticals’ anti-PD-L1 monoclonal antibody Cejemly (sugemalimab) for the treatment of adults with metastatic non-small-cell lung cancer (NSCLC). Pfizer’s gene therapy Durveqtix (fidanacogene elaparvovec) for the treatment of haemophilia B. AstraZeneca’s Fluenz (influenza vaccine [live attenuated, nasal]) for the prophylaxis of influenza in children and adolescents from 24 months to <18 years of age. Eckert & Ziegler’s GalliaPharm (germanium [68Ge] chloride / gallium [68Ga] chloride) for radiolabelling of various kits used for positron emission tomography (PET) imaging. Valneva’s Ixchiq (chikungunya vaccine [live]) to protect adults against disease caused by Chikungunya virus transmitted to humans by infected mosquitoes. Novo Nordisk’s Zegalogue (dasiglucagon) for the treatment of severe hypoglycaemia in adults, adolescents and children aged six years and over with diabetes mellitus. Bio-Thera Solutions’ biosimilar version of Avastin (bevacizumab), named Avzivi, for the treatment of carcinoma of the colon or rectum, breast cancer, NSCLC, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix. Five generic medicines also received a positive opinion: Apexelsin (paclitaxel) for the treatment of metastatic breast cancer; Dasatinib Accord Healthcare (dasatinib) for the treatment of chronic myelogenous leukaemia; and generic versions of pomalidomide from Accord Healthcare, Krka and Zentiva for treatment of multiple myeloma.Positive recommendations on extensions of therapeutic indication: Sanofi/Regeneron’s Dupixent (dupilumab) as an add-on maintenance treatment in adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils. Bristol Myers Squibb/Pfizer’s Eliquis (apixaban) to include the treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in paediatric patients from 28 days to <18 years of age. Calliditas Therapeutics/Stada’s Kinpeygo (budesonide) for the treatment of adults with primary immunoglobulin A nephropathy (IgAN). Mirum Pharmaceuticals’ Livmarli (maralixibat) to include progressive familial intrahepatic cholestasis in patients 3 months of age and older. AbbVie’s Skyrizi (risankizumab) for the treatment of adults with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional or biologic therapy. AstraZeneca’s Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adults with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. BeiGene’s Tevimbra (tislelizumab) alone for the treatment of adults with locally advanced or metastatic NSCLC after prior platinum-based therapy; in combination with pemetrexed and platinum‑containing chemotherapy for the first-line treatment of certain adults with non-squamous NSCLC whose tumours have PD-L1 expression on ≥50% of tumour cells with no EGFR or ALK positive mutations; and in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of certain adults with squamous NSCLC.Negative opinions on new medicines: The CHMP confirmed its initial recommendation to refuse the granting of a marketing authorisation for Neuraxpharm and Minoryx Therapeutics’ Nezglyal (leriglitazone) for the treatment of cerebral adrenoleukodystrophy.Withdrawal of applications: Cytokinetics pulled a filing seeking approval of Kinharto (omecamtiv mecarbil) for the treatment of adults with symptomatic chronic heart failure and reduced ejection fraction. The decision was based on feedback from the EMA that supporting results were not sufficient to conclude that the benefits of the cardiac myosin activator outweigh the risks. Cytokinetics recently outlined plans to conduct another study of Kinharto. Clinuvel withdrew an application to expand use of Scenesse (afamelanotide) into adolescents with erythropoietic protoporphyria. The drug has been approved in this indication in the EU since 2014 for adults. However, the company determined that it was not possible to provide the comprehensive safety and efficacy data expected by the EMA in the expanded population.

Drug ApprovalVaccineClinical Result

22 May 2024

·www.fiercepharma.com

Sanofi, Bristol Myers on the hook for $916M in do-over of Plavix marketing case in Hawaii

In the redo of a case that was overturned on an appeal, Bristol Myers Squibb and Sanofi have been ordered to pay $916 million to the state of Hawaii for their marketing of blood thinner Plavix. The award replaces a previous award of $834 million from three years ago. The companies will once again appeal. In the continuation of a decade-long legal battle, a Hawaii judge has ordered Bristol Myers Squibb and Sanofi to pay a combined $916 million to the state for failing to warn patients about the ineffectiveness of their blood thinner Plavix in some nonwhite patients. The award comes after a second trial in the case. Last year, following the first trial, which resulted in an $834 million award to the state in 2021, the Hawaii Supreme Court reversed in part and vacated in part the judgement, necessitating a redo. This time, the state court ruled in favor of Hawaii's allegation that the companies violated state consumer protection laws with their marketing of Plavix. In 2010, the FDA required Sanofi and BMS to include a boxed warning that Plavix could be less effective in nonwhite patients. Studies have shown that genetic differences—particularly in people of East Asian decent—can prevent some from metabolizing Plavix. The companies said they will appeal again. “Bristol Myers Squibb and Sanofi strongly disagree with the court’s penalty award,” the companies said in a joint statement. “The overwhelming body of scientific evidence demonstrates that Plavix is a safe and effective therapy, regardless of a patient’s race or genetics.” Judge James Ashford ruled that Sanofi and BMS knew that there was a risk “that about 30% of patients might have a diminished response to Plavix, but they did not update their label.” “The defendants created an environment where Hawaii prescribing physicians practiced for more than a decade without the necessary information needed to evaluate the serious limitations of this heart medication,” Ashford added. Plavix was approved in 1998, with generic versions (clopidogrel) controlling the market over the last decade. By way of settlements, Sanofi and BMS previously resolved lawsuits related to the drug in Louisiana, Mississippi, West Virginia and California. “The Hawai`i medical community recognizes the benefits of Plavix and continues to recommend it to Hawai`i patients without restrictions based on race, ethnicity or genetic status," the companies added. "The unprecedented penalties awarded in this case are unwarranted and out of proportion. This is the last remaining Plavix case and is a clear outlier given the companies’ successful defense of Plavix litigation in other states.”

Drug ApprovalPatent Infringement

100 Deals associated with Clopidogrel Bisulfate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00769	Clopidogrel Bisulfate	B01AC04	DB00758

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Non-Q wave myocardial infarction	EU	Teva Pharmaceuticals Europe BV	18 Feb 2015
Non-Q wave myocardial infarction	IS	Teva Pharmaceuticals Europe BV	18 Feb 2015
Non-Q wave myocardial infarction	LI	Teva Pharmaceuticals Europe BV	18 Feb 2015
Non-Q wave myocardial infarction	NO	Teva Pharmaceuticals Europe BV	18 Feb 2015
Atherosclerosis	EU	Pharmathen SA	27 Jul 2009
Atherosclerosis	IS	Pharmathen SA	27 Jul 2009
Atherosclerosis	LI	Pharmathen SA	27 Jul 2009
Atherosclerosis	NO	Pharmathen SA	27 Jul 2009
Non ST segment elevation acute coronary syndrome	EU	Teva Pharmaceuticals Europe BV	27 Jul 2009
Non ST segment elevation acute coronary syndrome	IS	Teva Pharmaceuticals Europe BV	27 Jul 2009
Non ST segment elevation acute coronary syndrome	LI	Teva Pharmaceuticals Europe BV	27 Jul 2009
Non ST segment elevation acute coronary syndrome	NO	Teva Pharmaceuticals Europe BV	27 Jul 2009
Angina, Stable	CN	Shenzhen Salubris Pharmaceuticals Co., Ltd.	01 Jan 2000
Cerebrovascular Disorders	CN	Shenzhen Salubris Pharmaceuticals Co., Ltd.	01 Jan 2000
Myocardial Ischemia	CN	Shenzhen Salubris Pharmaceuticals Co., Ltd.	01 Jan 2000
Non-St Elevated Myocardial Infarction	CN	Shenzhen Salubris Pharmaceuticals Co., Ltd.	01 Jan 2000
ST Elevation Myocardial Infarction	CN	Shenzhen Salubris Pharmaceuticals Co., Ltd.	01 Jan 2000
Acute Coronary Syndrome	EU	Sanofi Winthrop Industrie SA	14 Jul 1998
Acute Coronary Syndrome	IS	Sanofi Winthrop Industrie SA	14 Jul 1998
Acute Coronary Syndrome	LI	Sanofi Winthrop Industrie SA	14 Jul 1998

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart Defects, Congenital	Phase 3	US	Sanofi SA	01 Jan 2009
Heart Defects, Congenital	Phase 3	BR	Sanofi SA	01 Jan 2009
Heart Defects, Congenital	Phase 3	FR	Sanofi SA	01 Jan 2009
Heart Defects, Congenital	Phase 3	DE	Sanofi SA	01 Jan 2009
Heart Defects, Congenital	Phase 3	HU	Sanofi SA	01 Jan 2009
Heart Defects, Congenital	Phase 3	IN	Sanofi SA	01 Jan 2009
Heart Defects, Congenital	Phase 3	IT	Sanofi SA	01 Jan 2009
Heart Defects, Congenital	Phase 3	MY	Sanofi SA	01 Jan 2009
Heart Defects, Congenital	Phase 3	MX	Sanofi SA	01 Jan 2009
Heart Defects, Congenital	Phase 3	PL	Sanofi SA	01 Jan 2009

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03161678 (CTgov)	Phase 4	Thrombosis \| Blood Platelet Disorders \| Myocardial Infarction	111	clopidogrel+Ticagrelor (Wild-Type Genotype)	jqkrelmvcl(exmpmdcvwg) = xaedegzlhd qzntcldbkz (ihjovksajf, ydevexzrtm - etzlqjaucv) View more	-	06 May 2024
				clopidogrel+Ticagrelor (Carriers of the CES1 G143E Mutation)	jqkrelmvcl(exmpmdcvwg) = qjcpcfgdqt qzntcldbkz (ihjovksajf, aagjuxylbc - brccqluscx) View more
NCT04409834 (COVID-PACT, CTgov)	Phase 4	COVID-19 \| Arterial thrombosis \| Venous Thromboembolism	390	Unfractionated Heparin IV+Clopidogrel+Enoxaparin 1 mg/kg (Full-dose Anticoagulation (FDAC))	pixcajcnnh(jwpetomxyq) = qymsyrsznj ugehyisqas (ayweefzvlx, idlculxuim - tfznrvmjyz) View more	-	19 Jan 2024
				Unfractionated heparin SC+clopidogrel+Enoxaparin 40 mg SC (Standard-dose Prophylactic Anticoagulation (SDPAC))	pixcajcnnh(jwpetomxyq) = nuqnsoqvtx ugehyisqas (ayweefzvlx, ryjjwcoftw - cybopepwqu) View more
NCT03774394 (CTgov)	Phase 4	Chronic Kidney Diseases \| Coronary Artery Disease \| Diabetes Mellitus, Type 2	61	Clopidogrel+Clopidogrel active metabolite (Diabetes Mellitus Patients With Chronic Kidney Disease)	sogxhqlwdo(icqrabuumk) = ggxqjoqmrm hzrtacjetu (tidqspklmr, fyiagjdkpg - tgziijerwg) View more	-	21 Aug 2023
				Clopidogrel+Clopidogrel active metabolite (Diabetes Mellitus Patients Without Chronic Kidney Disease)	sogxhqlwdo(icqrabuumk) = hjletvkbvh hzrtacjetu (tidqspklmr, xftgbyymnd - wwpcihlxkg) View more
NCT03188705 (CTgov)	Phase 4	Thrombosis \| Occlusion of artery \| Drug Metabolism, Poor, CYP2C19-Related ... View more	6	Clopidogrel+Aspirin (Clopidogrel Alone Followed by Clopidogrel and Aspirin Treatment)	kancdnuzcz(sdocsiwhgk) = mkrpoxkwzp qmrlzfafqn (unqrqrdchv, sgtaqowgmo - nwtwiczgay) View more	-	15 Jun 2023
				Clopidogrel (Clopidogrel Alone Treatment)	qztswvaeja(hmtkphoxwb) = uqvmhwuxjp cupzpjyxgk (wrouqaitzy, ofutmnshhb - ftfejjkzvu) View more
NCT00979589 (CHANCE, Pubmed)	Phase 3	Stroke \| Ischemic Attack, Transient	2,853	Aspirin plus Clopidogrel	drotjwngaw(yeulcarxld) = maywzmybci psyhmwkcxz (vgqmomnzws ) View more	-	02 Jun 2023
				Aspirin alone	drotjwngaw(yeulcarxld) = bivmtdwuez psyhmwkcxz (vgqmomnzws ) View more
NCT01765400 (CTgov)	Phase 4	Heart Failure, Systolic	30	Prasugrel 10 mg daily x 2 weeks (Prasugrel)	nicotxxxch(mwxdokeekq) = sczdebqgtg khvezlrhau (qchdfbteoq, uzqeoqnzoz - ovliorgctv) View more	-	30 Nov 2022
				Clopidogrel 75 mg daily x 2 weeks (Clopidogrel)	nicotxxxch(mwxdokeekq) = iigcyhxels khvezlrhau (qchdfbteoq, pconsstxch - xpruljgzje) View more
NCT03207451 (CTgov)	Phase 4	Peripheral Vascular Diseases \| Coronary Artery Disease \| Myocardial Infarction	81	Vorapaxar (Vorapaxar)	lqavlcvxzv(ogbpjxvwrn) = qztujbogxm tigkqefitk (svjzunhoxt, vsvihghdep - awedyypiwn) View more	-	18 Aug 2022
				Clopidogrel (Vorapaxar and Clopidogrel)	lqavlcvxzv(ogbpjxvwrn) = pdbmdddzkc tigkqefitk (svjzunhoxt, hvzyfkjeuh - mhzjgddfzu) View more
STOPDAPT-2 (Pubmed)	Not Applicable	-	5,997	1-month DAPT followed by clopidogrel monotherapy	pkzvmshslw(scwrfqgjnz) = frfaycxwxy ajmzdnoqcj (adfzhbdwws, 0.21 - 0.70) View more	Positive	01 Aug 2022
				12-month DAPT with aspirin and clopidogrel	pkzvmshslw(scwrfqgjnz) = ermhxzdygu ajmzdnoqcj (adfzhbdwws ) View more
NCT01742117 (TAILOR-PCI Digital \| TAILOR-PCI, CTgov)	Phase 4	Acute Coronary Syndrome \| Coronary Artery Disease \| Constriction, Pathologic	5,276	Clopidogrel+Ticagrelor (Genotype-Guided Therapy)	bpzclfelav(txqziffqpx) = nugqvaemsc kqmhaptjtr (dphovzxkvr, fwstynexed - vpychkcivp) View more	-	09 Nov 2021
				Clopidogrel (Conventional Therapy)	bpzclfelav(txqziffqpx) = lrqoffcpww kqmhaptjtr (dphovzxkvr, ogwccnzmpf - umuuakkdnh) View more
NCT02217501 (CTgov)	Phase 3	Peripheral Arterial Disease	159	Acetylsalicylic acid (ASA)+clopidogrel (DAPT - Clinically Indicated Duration+12m)	tckqmdddhp(gvotyugrvj) = uatghvxipe heohmbageb (xbytgwknqv, bvkhqhqzme - qcyszlcpoj) View more	-	21 Feb 2021
				Acetylsalicylic acid (ASA)+clopidogrel (DAPT - Clinically Indicated Duration)	tckqmdddhp(gvotyugrvj) = pltzrpdjyc heohmbageb (xbytgwknqv, sevoyhvubh - htkuedgcyu) View more